Premium
Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting β‐catenin nuclear translocation
Author(s) -
Li Shizheng,
Wu Chunxia,
Fan Chenxing,
Zhang Puwei,
Yu Guifa,
Li Kun
Publication year - 2021
Publication title -
journal of biochemical and molecular toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.526
H-Index - 58
eISSN - 1099-0461
pISSN - 1095-6670
DOI - 10.1002/jbt.22620
Subject(s) - chromosomal translocation , doxorubicin , cancer research , catenin , breast cancer , chemistry , cancer cell , cancer , chemosensitizer , sensitization , chemotherapy , pharmacology , medicine , wnt signaling pathway , in vitro , immunology , cytotoxicity , signal transduction , biochemistry , gene
Numerous evidence link aberrant nuclear β‐catenin accumulation to the development of breast cancer resistance, therefore, targeted inhibition of β‐catenin nuclear translocation may effectively improve the chemosensitivity of breast cancer. Doxorubicin (Dox) is the most commonly used chemotherapeutic drug for breast cancer. Here, we determined that tanshinone II A (Tan II A) could improve the sensitivity of Dox‐resistant breast cancer MCF‐7/dox cells to Dox, and evaluated whether the sensitization effect of Tan II A on Dox was targeted to inhibit β‐catenin nuclear translocation. The results showed that Tan II A not only significantly inhibited the nuclear translocation of β‐catenin in MCF‐7/dox cells treated by Dox but also inhibited the nuclear translocation of β‐catenin in MCF‐7 cells treated by Dox to a certain degree. Furthermore, when the above two cells treated by Dox combined with Tan II A were intervened with β‐catenin agonist WAY‐262611, with the re‐nuclear translocation of β‐catenin in the cells, the sensitization effect of Tan II A on Dox was greatly reduced. These results indicated that Tan II A could improve the chemosensitivity of breast cancer cells to Dox by inhibiting β‐catenin nuclear translocation. Therefore, Tan II A could be used as a potential chemosensitizer in combination with Dox for breast cancer chemotherapy.